Clinical Trial Update: 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line therapy for colorectal cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: PD Dr. med. Volker Heinemann | Conditions: Neoplasm Metastasis, Colorectal Cancer | Phase 3 | Status: UNKNOWN